Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy

2019 ◽  
pp. 379-394
Author(s):  
Thomas Zander ◽  
Valentin Goede ◽  
Michael Hallek
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy

2020 ◽  
Vol 17 (3) ◽  
pp. 185-194
Author(s):  
Jared Freml ◽  
Thomas Delate ◽  
Jesus Hermosillo-Rodriguez
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Study ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer ◽  
Small Proportion ◽  
Biomarker Testing ◽  
Over Time

Aim: To describe pharmacogenomic tumor testing among patients with metastatic colorectal cancer. Methods: This was a retrospective study of patients with metastatic colorectal cancer diagnosed between 1 January 2014 and 30 June 2018. Patients were assessed for pharmacogenomic testing and appropriateness of chemotherapy use. Results: Overall, 112/167 (67.1%) patients had at least one of the three recommended pharmacogenomic tests and 41/167 (24.6%) had all tests. Twenty-four patients were treated with cetuximab with 8/167 (4.7%) identified as being treated with a RAS variant (n = 3) or incomplete testing (n = 5); thus, not in accordance with guidelines. Conclusion: Uptake of testing was variable but increased over time; however, a small proportion of patients received cetuximab with a variant or not all recommended tests being performed.

Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy

2017 ◽  
pp. 1-16
Author(s):  
Thomas Zander ◽  
Valentin Goede ◽  
Michael Hallek
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer

scholarly journals Disrupting the protein signaling activity of MAPK pathway as target for metastatic colorectal cancer therapy

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Augustine T. Nkembo ◽  
Nazarius S. Lamango ◽  
Yonghoa Jin ◽  
Nada Tawfeeq ◽  
Justin Mensah-Mamfo
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer ◽  
Mapk Pathway ◽  
Protein Signaling ◽  
Signaling Activity

Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada

2012 ◽  
Vol 48 (13) ◽  
pp. 1969-1976 ◽  
Author(s):  
Lindsay Hedden ◽  
Hagen Kennecke ◽  
Diego Villa ◽  
Karrisa Johnston ◽  
Caroline Speers ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
British Columbia ◽  
Cost Effectiveness ◽  
Cancer Therapy ◽  
Incremental Cost ◽  
Metastatic Colorectal Cancer

Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy

2012 ◽  
Vol 8 (4) ◽  
pp. 263-271 ◽  
Author(s):  
Fotios Loupakis ◽  
Marta Schirripa ◽  
Wu Zhang ◽  
Alfredo Falcone ◽  
Heinz-Josef Lenz
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapy ◽  
Metastatic Colorectal Cancer
Sign in / Sign up

Export Citation Format

Share Document